Elsevier, a global leader in scientific information and data analytics, and The American Society for Pharmacology and Experimental Therapeutics (ASPET) have announced a partnership to publish the Society’s four journals. ASPET’s journals, The Journal of Pharmacology and Experimental Therapeutics, Drug Metabolism and Disposition, Molecular Pharmacology and Pharmacological Reviews, will be published in collaboration with Elsevier beginning early next year. The partners are committed to a relationship that will allow long-term growth and security for the Society and its journals.
The ASPET-Elsevier partnership will expand the usage of innovative technologies leading to opportunities to increase submissions. ASPET staff and editors will have access to new analytical, bibliometric and plagiarism detection software tools. Authors will be able to publish free with no submission fees or page charges with an option for open access.
ASPET editors, journal boards, and staff will continue to manage the journals with full editorial control. ASPET and Elsevier will work together to ensure a smooth transition.
ASPET began publishing its first journal in 1908, and the Society has been committed to the success of its journals since then. The ASPET founders laid the groundwork for sharing science with the larger pharmacology community to help advance the science of drugs and therapeutics to accelerate the discovery of cures for disease.
ASPET’s move from a self-publishing model to a publisher-partnership with Elsevier will better serve its authors, reviewers, and the Society as a whole. ASPET’s already existing journals will remain hybrid, as access will continue to be subscription-based with the option for authors to publish as Open Access.
Click here to read the original press release.
